Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.91
ENZ's Cash to Debt is ranked higher than
59% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. ENZ: 1.91 )
ENZ' s 10-Year Cash to Debt Range
Min: 0.65   Max: No Debt
Current: 1.91

Equity to Asset 0.58
ENZ's Equity to Asset is ranked higher than
59% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. ENZ: 0.58 )
ENZ' s 10-Year Equity to Asset Range
Min: 0.57   Max: 0.97
Current: 0.58

0.57
0.97
F-Score: 3
Z-Score: -1.44
M-Score: -3.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -20.25
ENZ's Operating margin (%) is ranked higher than
58% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. ENZ: -20.25 )
ENZ' s 10-Year Operating margin (%) Range
Min: -50.6   Max: 16.64
Current: -20.25

-50.6
16.64
Net-margin (%) -19.46
ENZ's Net-margin (%) is ranked higher than
58% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. ENZ: -19.46 )
ENZ' s 10-Year Net-margin (%) Range
Min: -39.34   Max: 17.67
Current: -19.46

-39.34
17.67
ROE (%) -53.43
ENZ's ROE (%) is ranked higher than
50% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. ENZ: -53.43 )
ENZ' s 10-Year ROE (%) Range
Min: -79.98   Max: 9.17
Current: -53.43

-79.98
9.17
ROA (%) -30.93
ENZ's ROA (%) is ranked higher than
53% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. ENZ: -30.93 )
ENZ' s 10-Year ROA (%) Range
Min: -56.81   Max: 8.24
Current: -30.93

-56.81
8.24
ROC (Joel Greenblatt) (%) -159.38
ENZ's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. ENZ: -159.38 )
ENZ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -259.98   Max: 31.96
Current: -159.38

-259.98
31.96
Revenue Growth (%) -2.40
ENZ's Revenue Growth (%) is ranked higher than
63% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.40 vs. ENZ: -2.40 )
ENZ' s 10-Year Revenue Growth (%) Range
Min: -9.9   Max: 24.4
Current: -2.4

-9.9
24.4
EBITDA Growth (%) -8.50
ENZ's EBITDA Growth (%) is ranked higher than
62% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. ENZ: -8.50 )
ENZ' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 157.1
Current: -8.5

0
157.1
EPS Growth (%) -8.00
ENZ's EPS Growth (%) is ranked higher than
66% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. ENZ: -8.00 )
ENZ' s 10-Year EPS Growth (%) Range
Min: -24.6   Max: 58.7
Current: -8

-24.6
58.7
» ENZ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ENZ Guru Trades in Q1 2013

Jim Simons 234,900 sh (+14.03%)
» More
Q2 2013

ENZ Guru Trades in Q2 2013

Jim Simons 258,500 sh (+10.05%)
» More
Q3 2013

ENZ Guru Trades in Q3 2013

Jim Simons 283,900 sh (+9.83%)
» More
Q4 2013

ENZ Guru Trades in Q4 2013

Jim Simons 345,637 sh (+21.75%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZ



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.64
ENZ's P/B is ranked lower than
51% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. ENZ: 5.64 )
ENZ' s 10-Year P/B Range
Min: 0.85   Max: 7.24
Current: 5.64

0.85
7.24
P/S 1.87
ENZ's P/S is ranked higher than
79% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. ENZ: 1.87 )
ENZ' s 10-Year P/S Range
Min: 0.56   Max: 15.23
Current: 1.87

0.56
15.23

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.59
ENZ's Price/Tangible Book is ranked lower than
65% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. ENZ: 11.59 )
ENZ' s 10-Year Price/Tangible Book Range
Min: 1.97   Max: 29.77
Current: 11.59

1.97
29.77
Price/Median PS Value 0.63
ENZ's Price/Median PS Value is ranked higher than
88% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. ENZ: 0.63 )
ENZ' s 10-Year Price/Median PS Value Range
Min: 0.19   Max: 15.96
Current: 0.63

0.19
15.96
Earnings Yield (Greenblatt) 0.40
ENZ's Earnings Yield (Greenblatt) is ranked lower than
62% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. ENZ: 0.40 )
ENZ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 3.2
Current: 0.4

0.6
3.2
Forward Rate of Return (Yacktman) -4.53
ENZ's Forward Rate of Return (Yacktman) is ranked higher than
64% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.75 vs. ENZ: -4.53 )
ENZ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 29.1   Max: 37.9
Current: -4.53

29.1
37.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, IDXX » details
Traded in other countries:EZB.Germany
Enzo Biochem, Inc. is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company is conducting research and development activities in the development of therapeutic products based on the Company's technology platform of genetic modulation and immune modulation. The Company also operates a clinical laboratory that offers and provides diagnostic medical testing services to the health care community in the New York Metropolitan and New Jersey areas. The Company operates in three segments of which the Therapeutics and Life Sciences segments have evolved out of its core competencies. enzo Life Sciences manufactures, develops and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers world-wide and has amassed a large patent and technology portfolio, enzo Clinical Labs is a regional clinical laboratory serving the New York Metropolitan and New Jersey areas, enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of enzo Life Sciences. The Company has developed a portfolio of proprietary technologies with research, diagnostic and therapeutic applications. It is applying its core technologies to develop novel therapeutics as well as research tools for the life sciences and clinical diagnostics markets. In addition, The Company provides clinical laboratory services to physicians and other health care providers in the New York Metropolitan and New Jersey area. The Company is organized to the development, production, marketing and sales of innovative life science research reagents worldwide. The products supplied by Enzo Life Sciences include small molecules, proteins, antibodies, peptides, assay kits and custom services. Enzo Life Sciences is organized to promote and market its product through its seven brands Enzo, Alexis, Apotech, Axxora, Biomol, Assay Designs and Stressgen. Therapeutic Development Programs include Autoimmune Uveitis, Inflammatory bowel diseases. Osteoporosis (and certain bone disorders) and Diabetes, Non-Alcoholic SteatoHepatitis (NASH) and Human Immunodeficiency Virus (HIV-1). The Company competes with other life science and biotechnology companies, as well as pharmaceutical, chemical and other companies. The clinical laboratory industry is subject to federal and state regulation, including inspections and audits by governmental agencies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide